Authors’ response

We read the correspondence by Habibzadeh et al1 on our article2 with great interest. They stated that Perkins and Schisterman3, in their article clearly recommended the use of the Youden’s index (Se + Sp – 1) and warned about using the minimum distance criterion. We feel that the authors are overenthusiastic about the advantages of Youden’s Index1. Perkins and Schisterman3 have presented the following: “Since the (0,1) criterion is visually intuitive, we have provided an amended (0,1) criterion in Appendix 2 that is likewise geometrically satisfying while consistently dentifying the same “optimal” cutpoint as J”. They have also mentioned that the added advantage in using the Youden’s Index is the benefit of providing confidence interval and measurement of error. However, we would like to reiterate that Perkins and Schisterman3 have not categorically provided any kind of warning about using one statistic over another as stated by Habibzadeh et al1.

It is a known fact that the best cut-off is decided based on the scenario in which the proposed diagnostic test is going to be used, such as, whether the diagnostic test will be used as a “screening test” or as a “confirmatory test”. Researchers would like to have higher sensitivity if the diagnostic test is to be used as a screening test and choose a higher specificity if the diagnostic test is used as a confirmatory test. The researcher will have the flexibility to choose the cut-off based on the desired requirement. Thus, in a given clinical scenario, the cut-off values need not be decided only by (0,1) and Youden’s Index. The reliability of Youden’s Index has also been commented upon as well4.

The Youden’s index is optimal when the working procedure becomes the function of prevalence and the costs associated with false-positive and false-negative results. Thus, the cut-off decided using prevalence and cost is subject to further scrutiny at the place where it is being employed. As the prevalence and cost are likely to vary from place to place, many researchers repeat the study to validate the cut-off values.

Our aim was to generate and validate the cut-off that was reported by various studies5-7 and, therefore, we preferred to use the same method that was used in the previously published studies. Habibzadeh et al8 have presented two prevalence scenarios for diabetes mellitus, namely, 0.09 (in the community) and 0.41 (in referral hospital setting). They have stated “Suppose we want to use HbA1c as a screening test in general population in the studied region. Under such circumstance, the pr is no longer 0.41; it is 0.09 - the prevalence of type 2 diabetes in the studied region, Rayalaseema area in Andhra Pradesh, southern India.” and have quoted a study by Reddy et al9 as a reference for this figure of 0.09. Reddy et al9 did not conduct their study in a general population, but in “party workers belonging to a political party, drawn from each district of the then undivided Andhra Pradesh State who underwent an intensive training program”. These party workers were prospectively screened for the prevalence of coronary risk factors. As depicted in Table 3 of this article9, 153 of the 616 persons (25%) studied from Rayalseema area were found to have diabetes mellitus. It is not clear as to how the authors1 have derived the figure of 0.09 as the prevalence of diabetes mellitus in Rayalaseema area from this study9.

However, in order to do use glycosylated haemoglobin (HbA1c) as a diagnostic test for type 2 diabetes, the HbA1c estimation must be carried out on an instrument functioning on high-performance liquid chromatography (HPLC)-based ion exchange chromatography that conforms to the National Glycohemoglobin Standardization Program (NGSP) standardized to the Diabetes Control and Complications Trial (DCCT)10 as was used in our study2. In India, this facility is usually available in referral hospitals and large laboratories in big cities only. In many smaller cities, towns, and rural areas, practitioners use point-of-care (POC) diagnostic tests for HbA1c estimation instead of the above described standard method. The HbA1c estimation done anywhere and everywhere with non-standard POC machines cannot be used as a diagnostic test for diabetes mellitus. In the scenario in which HbA1c (estimated by the standard method as described above) is used as a diagnostic test for type 2 diabetes, the prevalence will be high. Moreover the prevalence of type 2 diabetes is high in the State of Andhra Pradesh10. Thus, the exercise using prevalence of 0.09 as proposed by the authors1 has little clinical relevance and constitutes a mere academic exercise.
Further, contrary to the argument raised by the Habibzadeh et al\(^1\) of using HbA\(_{1c}\) as a screening test in general population in the studied region, we wish to state that we have derived and validated a HbA\(_{1c}\) cut-off for use as a confirmatory diagnostic test (rather than a screening test) in a hospital-based scenario (rather than in a general population). We have also stated in the last sentence in the Discussion section\(^2\) that “...it would not be advisable to replace the oral glucose tolerance test (OGTT) by HbA1c as a diagnostic test for type 2 diabetes in the prevalence surveys in the general population.” We have also cautioned about the false-positive test results and stated that “However, the specificity was about 85 per cent which indicated that about 15-20 per cent of patients without type 2 diabetes would be wrongly labelled as having type 2 diabetes and would probably be started on unnecessary medication. While this may be resolved in a hospital-based situation on follow up of the patients, if HbA\(_{1c}\) is used as the diagnostic test in prevalence surveys of type 2 diabetes in the general population, the actual number of such misclassifications could be large\(^3\).”

In our study\(^2\) the Youden’s Index was 0.75; the HbA\(_{1c}\) cut-off that provided such index was >6.3; both (0,1) approach and the Youden’s Index provided the same cut-off. As a note of caution we feel that any recommendations that arise from simulated data with various prevalence and cost assumptions should also be given consideration in addition to data (study) driven recommendations alone.

Alladi Mohan\(^1\)*, S. Aparna Reddy\(^1\), Alok Sachan\(^2\), K.V.S. Sarma\(^3\), D. Prabath Kumar\(^4\), Mahesh V. Panchagnula\(^5\), P.V.L.N. Srinivasa Rao\(^6\), B. Siddhartha Kumar\(^7\) & P. Krishnaprasanthi\(^8\)

Departments of \(^1\)Medicine, \(^2\)Endocrinology and Metabolism & \(^3\)Biochemistry, Sri Venkateswara Institute of Medical Sciences, \(^4\)Department of Statistics, Sri Venkateswara University, \(^5\)Harshitha Hospitals, Tirupati & \(^6\)Department of Applied Mechanics, Indian Institute of Technology Madras, Chennai, India

*For correspondence: alladimohan@svims.gov.in

References
1. Habibzadeh F, Habibzadeh P, Yadollahie M. Choice of criterion used in the receiver operating characteristics analysis. Indian J Med Res 2017; 145 : 571-2.
2. Mohan A, Reddy SA, Sachan A, Sarma KVS, Kumar DP, Panchagnula MV, et al. Derivation & validation of glycosylated haemoglobin (HbA\(_{1c}\)) cut-off value as a diagnostic test for type 2 diabetes in south Indian population. Indian J Med Res 2016; 144 : 220-8.
3. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006; 163 : 670-5.
4. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden’s Index. Stat Med 1996; 15 : 969-86.
5. Mohan V, Vijayachandrika V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB, et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010; 33 : 515-9.
6. Kumar PR, Bhansali A, Ravikiran M, Bhansali S, Dutta P, Thakur JS, et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: A community-based study. J Clin Endocrinol Metab 2010; 95 : 2832-5.
7. Nair M, Prabhakaran D, Narayan KM, Sinha R, Lakshmy R, Devasenapathy N, et al. HbA\(_{1c}\) values for defining diabetes and impaired fasting glucose in Asian Indians. Prim Care Diabetes 2011; 5 : 95-102.
8. Reddy NK, Kumar DN, Rayudu NV, Sastry BK, Raju BS. Prevalence of risk factors for coronary atherosclerosis in a cross-sectional population of Andhra Pradesh. Indian Heart J 2002; 54 : 697-701.
9. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44 : 968-83.
10. Umnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol 2016; 12 : 357-70.